You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

435 Results
Guidelines and Advice
Status: Current
ID: ES 6-25
Oct 2024
Guidelines and Advice
Status: Current
ID: GL END 7-24
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abiraterone,
olaparib,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-2
Nov 2024
Document
Jan 2025
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-3
Mar 2025
Drug
Other Name(s): Tecentriq® SC
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Nivolumab - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
vinBLAStine,
dacarbazine,
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2025
Les fiches d’information sur les soins palliatifs pour les Autochtones sont élaborées afin de soutenir les membres des Premières Nations, des Inuits...
Document
Jun 2025
Document
Jun 2025
Drug
Other Name(s): Scemblix™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025

Pages